For the treatment of patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to crizotinib…

Think one step ahead With ALUNBRIG® (brigatinib)

See full indication

mousetrap

View the ALUNBRIG efficacy

Systemic Efficacy

Read about activity in the CNS

CNS Efficacy

Explore the safety profile

Safety

Learn about the once-daily dosing

Recommended Dosing


ALK+, anaplastic lymphoma kinase-positive; CNS, central nervous system; NSCLC, non-small cell lung cancer.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue >
Close

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel
Close